Literature DB >> 18786715

Hyperbaric oxygen therapy for treatment of adverse radiation effects after stereotactic radiosurgery of arteriovenous malformations: case report and review of literature.

John E Wanebo1, Grant A Kidd, Michael C King, Thomas S Chung.   

Abstract

BACKGROUND: Adverse radiation effects are a known complication after the use of SRS for AVMs, although it is difficult to predict which patients will manifest with these side effects. Treatment of swelling due to ARE is usually medical, but refractory cases may require surgical decompression. CASE DESCRIPTION: This report presents a case of a patient who experienced AREs after SRS (edema, headaches, and nausea) that failed to respond to steroid treatment but was successfully treated with HBO. The treatment characteristics of this and of 5 other cases of radiation injury after SRS for AVM managed with HBO therapy are reviewed, and the pathophysiology is discussed.
CONCLUSION: Hyperbaric oxygen therapy provides a therapeutic option to treat AREs following SRS of cerebral AVMs.

Entities:  

Mesh:

Year:  2008        PMID: 18786715     DOI: 10.1016/j.surneu.2008.03.037

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  3 in total

Review 1.  Treatment of pediatric cerebral radiation necrosis: a systematic review.

Authors:  N Drezner; K K Hardy; E Wells; G Vezina; C Y Ho; R J Packer; E I Hwang
Journal:  J Neurooncol       Date:  2016-07-20       Impact factor: 4.130

2.  Clinical, dosimetric, and radiographic correlation of radiation injury involving the brainstem and the medial temporal lobes following stereotactic radiotherapy for neoplasms of central skull base.

Authors:  Stefano Schipani; Rajan Jain; Keyur Shah; Jack P Rock; Benjamin Movsas; Mark Rosenblum; Samuel Ryu
Journal:  J Neurooncol       Date:  2010-04-08       Impact factor: 4.130

3.  Hyperbaric oxygen therapy for the treatment of radiation-induced macular ischemia.

Authors:  Shamim A Haji; Ronald Ep Frenkel
Journal:  Clin Ophthalmol       Date:  2010-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.